Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in <i>NPM1</i> mutated acute myeloid leukemia.

ABSTRACT: Detection of measurable residual disease (MRD) by mutation specific techniques has prognostic relevance in NPM1 mutated AML (NPM1 ^mut AML). However, the clinical utility of next generation sequencing (NGS) to detect MRD in AML remains unproven. We analysed the clinical significance of monitoring MRD using ultradeep NGS (NGS-MRD) and flow cytometry (FCM-MRD) in 137 samples obtained from 83 patients of NPM1 ^mut AML at the end of induction (PI) and consolidation (PC). We could monitor 12 different types of NPM1 mutations at a sensitivity of 0.001% using NGS-MRD. We demonstrated a significant correlation between NGS-MRD and real time quantitative PCR (RQ-PCR). Based upon a one log reduction between PI and PC time points we could classify patien

SUBMITTER: Patkar N 

PROVIDER: S-EPMC6290958 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature